Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug

Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, according to a press release from Natco
BusinessToday.In | April 26, 2021 | Updated 16:17 IST
NATCO is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients
The share price of Natco Pharma rose over 7 per cent today after the company announced that it has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.

Related Keywords

India ,Zydus Cadila ,Natco Pharma ,Central Drugs Standard Control Organization ,Molnupiravir Capsules ,Drugs Controller General ,Pegylated Interferon ,இந்தியா ,ஜய்துச் காடிலா ,நாட்கோ பார்மா ,மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் ,மருந்துகள் கட்டுப்படுத்தி ஜநரல் ,